Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | DDO | Q99489 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22159198 | 0.84 | BRD4 (0.54) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL20621731 | 0.83 | BRD4 (0.53) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL22035463 | 0.82 | BRD4 (0.51) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL8647980 | 0.82 | DAO (0.51) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL22184893 | 0.79 | IDH1 (0.42) | DAOKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22184898 | 0.79 | DAO (0.60) | DAODDOKDM4ETSHRALDH1A1 | |
| SCHEMBL7122481 | 0.77 | DAO (0.58) | DAOIDH1 | |
| SCHEMBL5475936 | 0.77 | KDM4E (0.48) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL22016193 | 0.76 | DAO (0.59) | DAOIDH1 | |
| SCHEMBL22016192 | 0.76 | DAO (0.59) | DAOIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116807912-A | Use of volatile components to limit or eliminate perception of malodor | 弗门尼舍有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | claimed |
| CN-111432851-A | Use of volatile ingredients to limit or eliminate perception of malodour | 弗门尼舍有限公司 | 2020-07-17 | — | — | CN | claimed |
| WO-2025245391-A1 | FRAGRANCE COMPOSITIONS WITH CONTROLLABLE ODOR PROFILES | TAKASAGO INTERNATIONAL CORPORATION (USA) (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250091984-A1 | FRAGRANCE AND FLAVOR MATERIALS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4504693-A1 | FRAGRANCE AND FLAVOR MATERIALS | Takasago International Corporation (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-118974009-A | Perfume and fragrance material | 高砂香料工业株式会社 | 2024-11-15 | — | — | CN | disclosed |
| US-12114681-B2 | Fragrance and flavor materials | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2024-10-15 | — | — | US | disclosed |
| US-11834408-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834408-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-12-05 | — | — | US | disclosed |
| CN-112638892-B | Perfume materials | 高砂香料工业株式会社 | 2023-11-21 | — | — | CN | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| US-7834000-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| US-7196079-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO, INC. (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091984-A1 | FRAGRANCE AND FLAVOR MATERIALS | TAS2R5, TAS2R8, NISCH | BRD4 1297/4885DAO 3647/4885DDO 2877/4885 |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | BRD4 1345/4885DAO 3361/4885DDO 3107/4885 |
| US-11834408-B2 | Compounds for the treatment of SARS | ACE2, SARS1, ACE | BRD4 153/4885DAO 2436/4885DDO 102/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | BRD4 145/4885DAO 456/4885DDO 1967/4885 |
| US-20080004261-A1 | CGRP receptor antagonists | CALCRL, CALCR, GRPR | BRD4 1345/4885DAO 3361/4885DDO 3107/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | BRD4 1892/4885DAO 4292/4885DDO 4190/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | BRD4 2493/4885DAO 4360/4885DDO 4302/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | BRD4 4435/4885DAO 1286/4885DDO 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.